Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-019 in healthy Japanese adults for COVID-19 prevention
jRCT2071200084Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing TAK-019 with Matching placebo (2 arms). Primary endpoints: Percentage of participants with solicited local adverse events after first vaccination, Percentage of participants with solicited local adverse events after second vaccination and 14 more. Started Feb 2021; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200084.